Recombinant human growth hormone: Old and novel uses

American Journal of Medicine

Volumn 105, Issue 1, 1998, Pages 44-57

  Tritos, Nicholas A ^a   Mantzoros, Christos S ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN GROWTH HORMONE; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C;

CHRONIC KIDNEY FAILURE; CRITICAL ILLNESS; DRUG INDICATION; GROWTH HORMONE DEFICIENCY; HORMONAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IDIOPATHIC DISEASE; PRIORITY JOURNAL; REVIEW; SHORT STATURE; TURNER SYNDROME; WASTING SYNDROME;

CLINICAL TRIALS; GROWTH HORMONE; HUMANS;

EID: 0032125723     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00135-1     Document Type: Review

References (203)

1. Bengtsson B.A. Growth hormone deficiency in adults a new indication for recombinant human growth hormone . J Intern Med. 239:1996;283-286.
2. Mantzoros C.S., Moses A.C. Whither recombinant human growth hormone? Ann Intern Med. 125:1996;932-934.
3. Marcus R., Reaven G.M. Growth hormone-ready for prime time? J Clin Endocrinol Metab. 82:1997;725-726.
4. Casanueva F.F. Physiology of growth hormone secretion and action. Endo Metab Clin North Am. 21:1992;483-517.
5. Smith R.G., Pong S.S., Hickey G., et al. Modulation of pulsatile growth hormone release through a novel receptor in hypothalamus and pituitary gland. Rec Prog Horm Res. 51:1996;261-286.
6. Ghigo E., Arvat E., Muccioli G., et al. Growth hormone releasing peptides. Eur J Endocrinol. 136:1997;445-460.
7. Zadik Z., Chalew S.A., McCarter R.J. Jr, et al. The influence of age on the 24 hour integrated concentration of growth hormone in normal individuals. J Clin Endocrinol Metab. 60:1985;513-516.
8. Hintz R.L., Suskind R., Amatayakul K., et al. Plasma somatomedin and growth hormone values in children with protein-calorie malnutrition. J Pediatr. 92:1978;153-156.
9. Bentham J., Rodriguez-Arnao J., Ross R.J. Acquired growth hormone resistance in patients with hypercatabolism. Horm Res. 40:1993;87-91.
10. Bondy C.A. Clinical uses of insulin-like growth factor I. Ann Intern Med. 120:1994;593-601.
11. Corpas E., Harman S.M., Blackman M.R. Human growth hormone and human aging. Endocr Rev. 14:1993;20-39.
12. Raben M.S. Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab. 18:1958;901-903.
13. Raben M.S. Clinical use of human growth hormone. NEJM. 266:1962;82-86.
14. Frasier S.D., Costin G., Lippe B.M., et al. A dose-response curve for human growth hormone. J Clin Endocrinol Metab. 53:1981;1213-1217.
15. Kaplan S.L., Underwood L.E., August G.P., et al. Clinical studies with recombinant-DNA-derived methionyl human growth hormone in growth hormone deficient children. Lancet. 1:1986;697-700.
16. Holcombe J.H., Conforti P.M., Wong A.C., et al. Biosynthetic human growth hormone in the treatment of growth hormone deficiency. Acta Pediatr Scand. 37:(suppl):1990;44-48.
17. Furlanetto R.W. Guidelines for the use of growth hormone in children with short stature a report by the Drug and Therapeutics Committee of the LWPES . J Pediatr. 127:1995;857-867.
18. Boot A.M., Engels M.A.M.J., Boerma G.J.M., et al. Changes in bone mineral density, body composition, and lipid metabolism during growth hormone treatment in children with growth hormone deficiency. J Clin Endocrinol Metab. 82:1997;2423-2428.
19. Fradkin J.E., Schonberger L.B., Mills J.L., et al. Creutzfeldt-Jacob disease in pituitary growth hormone recipients in the United States. JAMA. 265:1991;880-884.
20. Hintz R.L. The prismatic case of Creutzfeldt-Jacob disease associated with pituitary growth hormone treatment. J Clin Endocrinol Metab. 80:1995;2298-2301.
21. Goeddel D.V., Heyneker H.L., Hozum T. Direct expression in Escherichia coli of a DNA sequence coding for human growth hormone. Nature. 281:1979;544-548.
22. Rosenfeld R.G., Frane J., Attie K.M., et al. Six-year results of a randomized, prospective trial of human growth hormone and oxandrolone in Turner's syndrome. J Pediatr. 121:1992;49-55.
23. Nienhuis H.E., Rongen-Westerlaken C., Wit J.M., et al. Results of long-term therapy with growth hormone in two dose regimens in Turner's syndrome. Dutch Growth Hormone Working Group. Horm Res. 39:(suppl 2):1993;31-36.
24. Price D.A., Albertsson-Wikland K. Demography, auxology and response to recombinant human growth hormone treatment in girls with Turner's syndrome in the Kabi Pharmacia International Growth Study. International Board of the Kabi Pharmacia International Growth Study. Acta Paediatr. 82:(suppl 391):1993;69-74.
25. Broeck J.V.D., Massa G.G., Attanasio A., et al. Final height after long-term growth hormone treatment in Turner syndrome. J Pediatr. 127:1995;729-735.
26. Taback S.P., Collu R., Deal C.L., et al. Does growth hormone supplementation affect adult height in Turner's syndrome? Lancet. 348:1996;25-27.
27. Ross J.L., Feuillan P., Kushner K., et al. Absence of growth hormone effects on cognitive function in girls with Turner syndrome. J Clin Endocrinol Metab. 82:1997;1814-1817.
28. Mehls O., Haffner D., Wuhl E., et al. Growth hormone as a new treatment modality for short children with chronic renal failure. Horm Res. 46:1996;230-235.
29. Fine R.N., Kohaut E.C., Brown D., et al. Growth after recombinant human growth hormone treatment in children with chronic renal failure report of a multicenter randomized double-blind placebo-controlled study . J Pediatr. 124:1994;374-382.
30. Fine R.N. Recombinant human growth hormone in dialysis patients update 1995 . Adv Perit Dial. 11:1995;261-265.
31. Tonshoff B., Haffner D., Mehls O. Efficacy and safety of growth hormone treatment in short children with renal allografts three year experience . Kidney Int. 44:1993;199-207.
32. Hopwood N.J., Hintz R.L., Gertner J.M., et al. Growth response of non-growth hormone deficient children with marked short stature during three years of growth hormone therapy. J Pediatr. 123:1993;215-222.
33. Wit J.M., Kamp G.A., Rikken B. Spontaneous growth and response to growth hormone treatment in children with growth hormone deficiency and idiopathic short stature. Ped Res. 39:1996;295-302.
34. Zadik Z., Chalew S., Zung A., et al. Effect of long-term growth hormone therapy on bone age and pubertal maturation in boys with and without classical growth hormone deficiency. J Pediatr. 125:1994;189-195.
35. Hintz R.L., Attie K.M. Near final height in growth hormone-treated short children without classical growth hormone deficiency. Pediatr Res. 37:1995;91A. Abstract.
36. Hindmarsh P.C., Brook C.G.D. Final height of short normal children treated with growth hormone. Lancet. 348:1996;13-16.
37. Loche S., Cambiaso P., Setzu S., et al. Final height after growth hormone therapy in non-growth hormone-deficient children with short stature. J Pediatr. 125:1994;196-200.
38. Wit J.M., Boersma B., de Muinck Keizer-Schrama S.M., et al. Long-term results of growth hormone therapy in children with short stature, subnormal growth rate and normal growth hormone response to secretagogues Dutch growth hormone working group . Clin Endocrinol. 42:1995;365-372.
39. Kawai M., Momoi T., Yorifuji T., et al. Unfavorable effects of growth hormone therapy on the final height of boys with short stature not caused by growth hormone deficiency. J Pediatr. 130:1997;205-209.
40. Zegher F., Francois I., van Helvoirt M., et al. Small as fetus and short as child from endogenous to exogenous growth hormone . J Clin Endocrinol Metab. 82:1997;2021-2026.
41. Romano A.A., Blethen S.L., Dana K., et al. Growth hormone treatment in Noonan syndrome the National Cooperative Growth study experience . J Pediatr. 128:1996;S18-S21.
42. Anneren G., Gustafsson J., Sara V.R., et al. Normalized growth velocity in children with Down's syndrome during growth hormone therapy. J Intellect Disabil Res. 37:1993;381-387.
43. Lee P.D., Hwu K., Henson H., et al. Body composition studies in Prader-Willi syndrome effect of growth hormone therapy . Basic Life Sci. 60:1993;201-205.
44. Rotenstein D., Breen T.J. Growth hormone treatment of children with myelomeningocele. J Pediatr. 128:1996;S28-S31.
45. Bridges N.A., Brook C.G. Progress report growth hormone in skeletal dysplasia . Horm Res. 42:1994;231-234.
46. Shohat M., Tick D., Barakat S., et al. Short-term recombinant human growth hormone treatment increases growth rate in achondroplasia. J Clin Endocrinol Metab. 81:1996;4033-4037.
47. Saggese G., Baroncelli G.I., Bertelloni S., et al. Long-term growth hormone treatment in children with renal hypophosphatemic rickets effects on growth, mineral metabolism and bone density . J Pediatr. 127:1995;395-402.
48. Sarna S., Sipila I., Ronnholm K., et al. Recombinant human growth hormone improves growth in children receiving glucocorticoid treatment after liver transplantation. J Clin Endocrinol Metab. 81:1996;1476-1482.
49. Loke K.Y., Yap H.K., Zhou Z., et al. Efficacy and safety of one year of growth hormone therapy in steroid-dependent nephrotic syndrome. J Pediatr. 130:1997;793-799.
50. Committee on Drugs and Committee on Bioethics. Considerations related to the use of growth hormone in children. Pediatrics. 99:1997;122-129.
51. Salomon F., Cuneo R.C., Hesp R., et al. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. NEJM. 321:1989;1797-1803.
52. DeBoer H., Blok G.J., Voerman H.J., et al. Body composition in adult growth hormone deficient men, assessed by anthropometry and bioimpedance analysis. J Clin Endocrinol Metab. 75:1992;833-837.
53. Rosen T., Boseaus I., Tolli J., et al. Increased body fat mass and decreased extracellular fluid volume in adults with growth hormone deficiency. Clin Endocrinol. 38:1993;63-71.
54. Salomon F., Cuneo R.C., Sonksen P.H. Glucose metabolism in adults with growth hormone deficiency. Acta Pediatr Scand. 377:(suppl):1991;64-68.
55. Johansson J.O., Fowelin J., Landin K., et al. Growth hormone deficient adults are insulin resistant. Metabolism. 44:1995;1126-1129.
56. Mantzoros C.S., Flier J.S. Insulin resistance the clinical spectrum . Adv Endocrinol. 6:1995;193-232.
57. Amato G., Carella C., Fazio S., et al. Body composition, bone metabolism and heart structure and function in growth hormone deficient adults before and after growth hormone replacement therapy at low doses. J Clin Endocrinol Metab. 77:1993;1671-1676.
58. De Boer H., Blok G.J., Van Lingen A., et al. Consequences of childhood-onset growth hormone deficiency for adult bone mass. J Bone Miner Res. 9:1994;1319-1326.
59. Rosen T., Hansson T., Granhed H., et al. Reduced bone mineral content in adult patients with growth hormone deficiency. Acta Endocrinol. 129:1993;201-206.
60. Holmes S.J., Economou G., Whitehouse R.W., et al. Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab. 78:1994;669-674.
61. Rosen T., Eden S., Larsson G., et al. Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol. 129:1993;195-200.
62. Eden S., Wiklund O., Oscarsson J., et al. Growth hormone treatment of growth hormone deficient adults results in a marked increase in Lp (a) and HDL cholesterol concentrations. Arterioscler Thromb. 13:1993;296-301.
63. Johansson J.O., Landlin K., Tengborn L., et al. High fibrinogen and plasminogen activator inhibitor activity in growth hormone deficient adults. Arterioscler Thromb. 14:1994;434-437.
64. Cummins M.H., Christ E., Umpleby A.M., et al. Abnormalities of VLDL apo B-100 metabolism contribute to the dyslipidemia of adult growth hormone deficiency. J Clin Endocrinol Metab. 82:1997;2010-2013.
65. Markussis V., Beshyah S.A., Fischer C., et al. Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults. Lancet. 340:1992;1188-1192.
66. Rosen T., Bengtsson B.A. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet. 336:1990;285-288.
67. Cuneo R.C., Salomon F., Wiles C.M., et al. Growth hormone treatment in growth hormone deficient adults. Effects on exercise performance. J Appl Physiol. 70:1991;695-700.
68. Sacca L., Cittadini A., Fazio S. Growth hormone and the heart. End Rev. 15:1994;555-573.
69. Sacca L., Fazio S. Cardiac performance growth hormone enters the race . Nat Med. 2:1996;29-31.
70. Cuneo R.C., Wilmshurst P., Lowy C., et al. Cardiac failure responding to growth hormone. Lancet. I:(8642):1989;838-839.
71. Fazio S., Biondi B., Sabatini D., et al. Long-term growth hormone deficiency as a cause of cardiomyopathy and its reversibility with specific replacement therapy. J Clin Endocrinol Metab. 81:1996;887-890.
72. Caidahl K., Eden S., Bengtsson B.A. Cardiovascular and renal effects of growth hormone. Clin Endocrinol. 40:1994;393-400.
73. Valcavi R., Gaddi O., Zini M., et al. Cardiac performance and mass in adults with hypopituitarism effects of one year of growth hormone treatment . J Clin Endocrinol Metab. 80:1995;659-666.
74. Powrie J., Weissberger A., Sonksen P. Growth hormone replacement therapy for growth hormone deficient adults. Drugs. 49:1995;656-663.
75. McGauley G.A. Quality of life assessment before and after growth hormone treatment in adults with growth hormone deficiency. Acta Pediatr Scand. 356:(suppl):1989;70-72.
76. Stabler B., Turner J.R., Girdler S.S., et al. Reactivity to stress and psychological adjustment in adults with pituitary insufficiency. Clin Endocrinol. 36:1992;467-473.
77. Rosen T., Wiren L., Wilhlmsen L., et al. Decreased psychological well-being in adult patients with growth hormone deficiency. Clin Endocrinol. 40:1994;111-116.
78. Cuneo R.C., Salomon F., McGauley G.A., et al. The growth hormone deficiency syndrome in adults. Clin Endocrinol. 37:1992;387-397.
79. Bengtsson B.A. The consequences of growth hormone deficiency in adults. Acta Endocrinol. 128:1993;2-5.
80. Hoffman D.M., O'Sullivan A.J., Baxter R.C., et al. Diagnosis of growth hormone deficiency in adults. Lancet. 343:1994;1064-1068.
81. Svensson J., Johannsson G., Bengtsson B.A. IGF I in growth hormone deficient adults relationship to population based normal values, body composition and insulin tolerance test . Clin Endocrinol. 46:1997;579-586.
82. Baum H.B.A., Biller B.M.K., Katznelson L., et al. Assessment of growth hormone secretion in men with adult-onset growth hormone deficiency compared with that in normal men - a clinical research center study. J Clin Endocrinol Metab. 81:1996;84-92.
83. Ho K.K.Y., Hoffman D.M. Defining growth hormone deficiency in adults. Metabolism. 44:1995;91-96.
84. Thorner M.O., Bengtsson B.A., Ho K.Y., et al. The diagnosis of growth hormone deficiency in adults. J Clin Endocrinol Metab. 80:1995;3097-3098.
85. Toogood A.A., Beardwell C.G., Shalet S.M. The severity of growth hormone deficiency in adults with pituitary disease is related to the degree of hypopituitarism. Clin Endocrinol. 41:1994;511-516.
86. Nicolson A., Toogood A., Rahim A., et al. The prevalence of severe growth hormone deficiency in adults who received growth hormone replacement in childhood. Clin Endocrinol. 44:1996;311-316.
87. Juul A., Kastrup K.W., Pedersen S.A., et al. Growth hormone provocative retesting of 108 young adults with childhood-onset growth hormone deficiency and the diagnostic value of IGF I and IGFBP 3. J Clin Endocrinol Metab. 82:1997;1195-1201.
88. The specificity of growth hormone stimulation tests in childhood and adolescence. Clin Invest Med. 13:(suppl):1990;B28.
89. Jorgensen J.O., Pedersen S.A., Thuesen L., et al. Beneficial effects of growth hormone treatment in growth hormone deficient adults. Lancet. 1989;1221-1225.
90. Whitehead H.M., Boreham C., Mellrath E.M., et al. Growth hormone treatment of adults with growth hormone deficiency results of a 13 month placebo controlled crossover study . Clin Endocrinol. 36:1992;45-52.
91. Bengtsson B.A., Eden S., Lonn L., et al. Treatment of adults with recombinant human growth hormone deficiency. J Clin Endocrinol Metab. 76:1993;309-317.
92. Jorgensen J.O., Thuesen L., Muller J., et al. Three years of growth hormone treatment in growth hormone deficient adults near-normalization of body composition and physical performance . Eur J Endocrinol. 130:1994;224-228.
93. Ho K.Y., Weissberger A.J. The antinatriuretic action of biosynthetic human growth hormone in man involves activation of the renin-angiotensin system. Metabolism. 39:1990;133-137.
94. Vandeweghe M., Taclman P., Kaufman J.M. Short and long-term effects of growth hormone treatment on bone turnover and bone mineral content in adult growth-hormone deficient males. Clin Endocrinol. 39:1993;409-414.
95. Baum H.B.A., Biller B.M.K., Finkelstein J.S., et al. Effects of low dose growth hormone administration on bone density and bone composition in patients with adult-onset growth hormone deficiency. Ann Intern Med. 125:1996;883-890.
96. O'Halloran D.J., Tsatsoulis A., Whitehouse R.W., et al. Increased bone mineral density after recombinant human growth hormone therapy in adults with isolated growth hormone deficiency. J Clin Endocrinol Metab. 76:1993;1344-1348.
97. Rosen T., Johannsson G., Hallgren P., et al. Beneficial effects of twelve months replacement therapy with recombinant human growth hormone to growth hormone deficient adults. Endocrinol Metab. 1:1994;55-66.
98. Holmes S.J., Whitehouse R.W., Swindell R., et al. Effect of growth hormone replacement on bone mass in adults with adult onset growth hormone deficiency. Clin Endocrinol. 42:1995;627-633.
99. Hansen T.B., Brixen K., Vahl N., et al. Effects of 12 months of growth hormone treatment on calciotropic hormones, calcium homeostasis and bone metabolism in adults with acquired growth hormone deficiency a double blind, randomized, placebo-controlled study . J Clin Endocrinol Metab. 81:1996;3352-3359.
100. Holmes S.J., Whitehouse R.W., Economou G., et al. Further increase in forearm cortical bone mineral content after discontinuation of growth hormone replacement. Clin Endocrinol. 42:1995;3-7.
101. Nass R., Huber R.M., Klauss V., et al. Effect of hgrowth hormone replacement therapy on physical work capacity and cardiac and pulmonary function in patients with growth hormone deficiency acquired in adulthood. J Clin Endocrinol Metab. 80:1995;552-557.
102. Johnston D.G., Bengtsson B.A. Workshop report the effects of growth hormone and growth hormone deficiency on lipids and the cardiovascular system . Acta Endocrinol. 128:(suppl 2):1993;69-70.
103. Johannsson G., Oscarsson J., Rosen T., et al. Effects of one year of growth hormone therapy on serum lipoprotein levels in growth hormone deficient adults. Influence of gender and apo (a) and apoE phenotypes. Arterioscler Thromb Vasc Biol. 15:1995;2142-2150.
104. Beshyah S.A., Henderson A., Niththyananthan R., et al. The effects of short and long term growth hormone replacement therapy in hypopituitary adults on lipid metabolism and carbohydrate tolerance. J Clin Endocrinol Metab. 80:1995;356-363.
105. Weaver J.U., Monson J.P., Noonan K., et al. The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity and cardiovascular risk factors in hypopituitary adults. J Clin Endocrinol Metab. 80:1995;153-159.
106. Laron Z., Wang X.L., Klinger B., et al. Growth hormone increases and IGF I decreases circulating lipoprotein (a). Eur J Endocrinol. 136:1997;377-381.
107. Johansson J.O., Larsson G., Elmgren A., et al. Treatment of growth hormone-deficient adults with recombinant human growth hormone increases the concentration of growth hormone in the cerebrospinal fluid and affects neurotransmitters. Neuroendocrinology. 61:1995;57-66.
108. Burman P., Hetta J., Wide L., et al. Growth hormone treatment affects brain neurotransmitters and thyroxine. Clin Endocrinol. 44:1996;319-324.
109. Attanasio A.F., Lamberts S.W.J., Matranga A.M.C., et al. Adult growth hormone deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human growth hormone treatment. J Clin Endocrinol Metab. 82:1997;82-88.
110. Burman P., Johansson A.G., Siegbahn A., et al. Growth hormone deficient men are more responsive to growth hormone replacement therapy than women. J Clin Endocrinol Metab. 82:1997;550-555.
111. Rudman D., Feller A.G., Nagraj H.S., et al. Effects of human growth hormone in men over 60 years old. NEJM. 323:1990;1-9.
112. Papadakis M.A., Grady D., Black D., et al. Growth hormone replacement therapy in healthy older men improves body composition but not functional ability. Ann Intern Med. 124:1996;708-716.
113. Welle S., Thornton C., Statt M., et al. Growth hormone increases muscle mass and strength but does not rejuvenate myofibrillar protein synthesis in healthy subjects over 60 years old. J Clin Endocrinol Metab. 81:1996;3239-3243.
114. Taaffe D.R., Pruitt L., Reim J., et al. Effect of recombinant human growth hormone on the muscle strength response to resistance exercise in elderly men. J Clin Endocrinol Metab. 79:1994;1361-1366.
115. Yarasheski K.E., Campbell J.A., Smith K., et al. Effect of growth hormone and resistance exercise on muscle growth in young men. Am J Physiol. 262:(3 Pt 1):1992;E261-E267.
116. Bonjour J.P., Theintz G., Buchs B., et al. Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. J Clin Endocrinol Metab. 73:1991;555-563.
117. Holloway L., Butterfield G., Hintz R.L., et al. Effects of recombinant human growth hormone on metabolic indices, body composition and bone turnover in healthy elderly women. J Clin Endocrinol Metab. 79:1994;470-479.
118. Johansson A.G., Lindh E., Blum W.F., et al. Effects of growth hormone and IGF I in men with idiopathic osteoporosis. J Clin Endocrinol Metab. 81:1996;44-48.
119. Aloia J.F., Vaswani A., Kapoor A., et al. Treatment of osteoporosis with calcitonin, with and without growth hormone. Metabolism. 34:1985;124-129.
120. Gonnelli S., Cepollaro C., Montomoli M., et al. Treatment of postmenopausal osteoporosis with recombinant human growth hormone and salmon calcitonin a placebo controlled study . Clin Endocrinol. 46:1997;55-61.
121. Holloway L., Kohlmeier L., Kent K., et al. Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteoporotic postmenopausal women. J Clin Endocrinol Metab. 82:1997;1111-1117.
122. Deal C.L. Osteoporosis prevention, diagnosis and management . Am J Med. 102:1997;35S-39S.
123. Fazio S., Sabatini D., Capaldo B., et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. NEJM. 334:1996;809-814.
124. Johannsson G., Marin P., Lonn L., et al. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism and reduces diastolic blood pressure. J Clin Endocrinol Metab. 82:1997;727-734.
125. Marin P., Kvist H., Lindstedt G., et al. Low concentrations of insulin-like growth factor I in abdominal obesity. Int J Obesity Relat Metab Disord. 17:1993;83-89.
126. Veldhuis J.D., Liem A.Y., South S., et al. Differential impact of age, sex steroid hormones and obesity on basal vs pulsatile growth hormone secretion in men as assessed in an ultrasensitive chemiluminescence assay. J Clin Endocrinol Metab. 80:1995;3209-3222.
127. Jenkins R.C., Ross R.J.M. Growth hormone therapy for protein catabolism. Q J Med. 89:1996;813-819.
128. Koea J.B., Douglas R.G., Shaw J.H., et al. Growth hormone therapy initiated before starvation ameliorates the catabolic state and enhances the protein-sparing effect of total parenteral nutrition. Br J Surg. 80:1993;740-744.
129. Vara-Thorbeck R., Guerrero J.A., Rosell J., et al. Exogenous growth hormone effects on the catabolic response to surgically produced acute stress and on postoperative immune function . World J Surg. 17:1993;530-538.
130. Hill G.L. Invited commentary. World J Surg. 17:1993;537-538.
131. Herndon D.N., Barrow R.E., Kunkel K.R., et al. Effects of recombinant human growth hormone on donor-site healing in severely burned children. Ann Surg. 212:1990;424-429.
132. Knox J.B., Demling R.H., Wilmore D.W., et al. Increased survival after major thermal injury the effect of growth hormone therapy in adults . J Trauma. 39:1995;526-530.
133. Petersen S.R., Holaday N.J., Jeevanandam M. Enhancement of protein synthesis efficiency in parenterally fed trauma victims by adjuvant rhgrowth hormone. J Trauma. 36:1994;726-733.
134. Behrman S.W., Kudsk K.A., Brown R.O., et al. The effect of growth hormone on nutritional markers in enterally fed immobilized trauma patients. J Parenter Enteral Nutr. 19:1995;41-46.
135. Pape G.S., Friedman M., Underwood L.E., et al. The effect of growth hormone on weight gain and pulmonary function in patients with chronic obstructive lung disease. Chest. 99:1991;1495-1500.
136. Suchner U., Rothkopf M.M., Stanislaus G., et al. Growth hormone and pulmonary disease metabolic effects in patients receiving parenteral nutrition . Arch Intern Med. 150:1990;1225-1230.
137. Wolf R.F., Pearlstone D.B., Newman E., et al. Growth hormone and insulin reverse net whole body and skeletal muscle protein catabolism in cancer patients. Ann Surg. 216:1992;280-288.
138. Tayek J.A., Brasel J.A. Failure of anabolism in malnourished cancer patients receiving growth hormone a clinical research center study . J Clin Endocrinol Metab. 80:1995;2082-2087.
139. Knox J.B., Wilmore D.W., Demling R.H., et al. Use of growth hormone for postoperative respiratory failure. Am J Surg. 171:1996;576-580.
140. Mulligan K., Grunfeld C., Hellerstein M.K., et al. Anabolic effects of rhgrowth hormone in patients with wasting associated with HIV infection. J Clin Endocrinol Metab. 77:1993;956-962.
141. Krentz A.J., Koster F.T., Crist D.M., et al. Anthropometric, metabolic and immunological effects of rhgrowth hormone in AIDS and AIDS-related complex. J AIDS. 6:(3):1993;245-251.
142. Schambelan M., Mulligan K., Grunfeld C., et al. A controlled trial of recombinant human growth hormone in patients with HIV associated wasting. Ann Intern Med. 125:1996;873-882.
143. Steele F.R. Growth hormone and AIDS related wasting. Nat Med. 2:1996;369-370.
144. Agus M.S., Katz L.E., Satin-Smith M., et al. Non-islet-cell tumor associated with hypoglycemia in a child successful long-term therapy with growth hormone . J Pediatr. 127:1995;403-407.
145. Baxter R.C. The role of IGFs and their binding proteins in tumor hypoglycemia. Horm Res. 46:1996;195-201.
146. Byrne T.A., Morrissey T.B., Gatzen C., et al. Anabolic therapy with growth hormone accelerates protein gain in surgical patients requiring nutritional rehabilitation. Ann Surg. 218:1993;400-418.
147. Byrne T.A., Persinger R.L., Young L.S., et al. A new treatment for patients with short-bowel syndrome growth hormone, glutamine and a modified diet . Ann Surg. 222:1995;243-255.
148. Homburg R., Levy T., Ben-Rafael Z. Adjuvant growth hormone for induction of ovulation with GnRH agonist and gonadotropins in polycystic ovary syndrome a randomized, double blind, placebo controlled trial . Hum Reprod. 10:1995;2550-2553.
149. Homburg R., Eshel A., Abdalla H.I., et al. Growth hormone facilitates ovulation induction by gonadotropins. Clin Endocrinol. 29:1988;113-117.
150. Shoham Z., Conway G.S., Ostergard H., et al. Cotreatment with growth hormone for induction of spermatogenesis in patients with hypogonadotropic hypogonadism. Fertil Steril. 57:1992;1044-1051.
151. Younis J.S., Simon A., Koren R., et al. The effect of growth hormone supplementation on in vitro fertilization outcome a prospective randomized placebo-controlled double-blind study . Fertil Steril. 58:1992;575-580.
152. Owen E.J., Shoam Z., Mason B.A., et al. Cotreatment with growth hormone, after pituitary suppression, for ovarian stimulation in in vitro fertilization a randomized, double blind, placebo-controlled trial . Fertil Steril. 56:1991;1104-1110.
153. Bergh C., Hillensjo T., Wikland M., et al. Adjuvant growth hormone treatment during in vitro fertilization a randomized, placebo-controlled study . Fertil Steril. 62:1994;113-120.
154. DeBoer H., Blok G.J., Van Der Veen E.A. Clinical aspects of growth hormone deficiency in adults. End Rev. 16:1995;63-86.
155. Chipman J.J., Attanasio A.F., Birkett M.A., et al. The safety profile of growth hormone replacement therapy in adults. Clin Endocrinol. 46:1997;473-481.
156. Cohn L., Feller A.G., Draper M.W., et al. Carpal tunnel syndrome and gynecomastia during growth hormone treatment of elderly men with low circulating IGF-I concentrations. Clin Endocrinol. 39:1993;417-425.
157. Binnerts A., Swart G.R., Wilson J.H.P., et al. The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis as well as on body composition. Clin Endocrinol. 37:1992;79-87.
158. Fowelin J., Attvall S., Lager I., et al. Effects of treatment with recombinant human growth hormone on insulin sensitivity and glucose intolerance in adults with growth hormone deficiency. Metabolism. 42:1993;1443-1447.
159. Johansson J.O., Oscarsson J., Bjarnason R., et al. Two weeks of daily injections and continuous infusion of recombinant human growth hormone in growth hormone deficient adults effects on IGF-I, growth hormone and IGF binding proteins and glucose homeostasis . Metabolism. 45:1996;362-369.
160. Marcus R., Butterfield G., Holloway L., et al. Effects of short-term administration of recombinant human growth hormone to elderly people. J Clin Endocrinol Metab. 70:1990;519-527.
161. Hintz R.L. Untoward events in patients treated with growth hormone in the USA. Horm Res. 38:(suppl 1):1992;44-49.
162. Malozowski S., Tanner L.A., Wysowski D.K., et al. Benign intracranial hypertension in children with growth hormone deficiency treated with growth hormone. J Pediatr. 126:1995;996-999.
163. Malozowski S., Hung W., Scott D.C., et al. Acute pancreatitis associated with growth hormone therapy for short stature. NEJM. 332:1995;401-402.
164. Bengtsson B.A., Eden S., Ernest I., et al. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand. 223:1988;327-335.
165. Bengtsson B.A. Acromegaly and neoplasia. J Pediatr Endocrinol. 6:1993;73-78.
166. Mantzoros C.S., Tzonou A., Signorello L.B., et al. IGF I in relation to prostate cancer and benign prostate hyperplasia. Br J Cancer. 76:1997;1115-1118.
167. Chan J.M., Stampfer M.J., Giovannucci E., et al. Circulating insulin-like growth factor I and prostate cancer risk a prospective study . Science. 279:1998;563-566.
168. Wolk A, Mantzoros CS, Andersson SO, et al. IGF I and IGFBP 3 in relation to prostate cancer: a population-based case-control study in Sweden. J Natl Cancer Inst 1998. In press.
169. Hankinson S., Pollak M., Michaud D., et al. A prospective assessment of plasma insulin-like growth factor levels and breast cancer risk. Am J Epidemiol. 145:1997;S72.
170. Bruning P.F., Van Doorn J., Bonfrer J.M.G., et al. Insulin like growth factor binding protein 3 is decreased in early-stage operable premenopausal breast cancer. Int J Cancer. 62:1995;266-270.
171. Bohlke K, Cramer DW, Trichopoulos D, Mantzoros CS. Insulin-like growth factor I in relation to premenopausal ductal carcinoma in situ of the breast: a case-control study. Epidemiology 1998. In press.
172. Ng S.T., Zhou J., Adesanya O.O., et al. Growth hormone treatment induces mammary gland hyperplasia in aging primates. Nat Med. 3:1997;1141-1144.
173. Fort S., Weaver J.U., Monson J.P., et al. The effects of low-dose recombinant human growth hormone on cardiovascular structure and function in hypopituitary growth hormone-deficient adults. Endocrinol Metab. 2:1995;119-126.
174. Watanabe S., Mizuno S., Oshima L.H. Leukemia and other malignancies among growth hormone users. J Pediatr Endocrinol. 6:1993;99-108.
175. Fradkin J.E., Mills J.L., Schonberger L.B., et al. Risk of leukemia after treatment with pituitary growth hormone. JAMA. 270:1993;2829-2832.
176. Allen D.B. Safety of human growth hormone therapy current topics . J Pediatr. 128:1996;S8-S13.
177. Moshang T. Jr, Rundle A.C., Graves D.A., et al. Brain tumor recurrence in children treated with growth hormone the National Cooperative Growth Study experience . J Pediatr. 128:1996;S4-S7.
178. Blethen S.L., Allen D.B., Graves D., et al. Safety or recombinant DNA-derived growth hormone the National Cooperative Growth Study experience . J Clin Endocrinol Metab. 81:1996;1704-1710.
179. Bourguignon J.P., Pierard G.E., Ernould C., et al. Effects of human growth hormone therapy on melanocytic nevi. Lancet. 341:1993;1505-1506.
180. Rosen T., Johansson G., Johansson J.O., et al. Consequences of growth hormone deficiency in adults and the benefits and risks of recombinant human growth hormone treatment. Horm Res. 43:1995;93-99.
181. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency . J Clin Endocrinol Metab. 83:1998;379-381.
182. Pihoker C., Middleton R., Reynolds G.A., et al. Diagnostic studies with intravenous and intranasal growth hormone-releasing peptide-2 in children of short stature. J Clin Endocrinol Metab. 80:1995;2987-2992.
183. Laron Z., Frenkel J., Deghenghi R., et al. Intranasal administration of the growth hormone releasing peptide hexarelin accelerates growth in short children. Clin Endocrinol. 43:1995;631-635.
184. Loche S., Colao A., Cappa M., et al. The growth hormone response to hexarelin in children reproducibility and effect of sex steroids . J Clin Endocrinol Metab. 82:1997;861-864.
185. Vittone J., Blackman M.R., Busby-Whitehead J., et al. Effects of single nightly injections of growth hormone-releasing hormone (growth hormone releasing hormone 1-29) in healthy elderly men. Metabolism. 46:1997;89-96.
186. Klinger B., Laron Z. Three-year IGF-I treatment of children with Laron syndrome. J Pediatr Endocrinol Metab. 8:1995;149-158.
187. Backeljauw P.F., Underwood L.E. Prolonged treatment with recombinant IGF-I in children with growth hormone insensitivity syndrome - a clinical research center study. J Clin Endocrinol Metab. 81:1996;3312-3317.
188. Thoren M.C., Wivall-Helleryd I.L., Blum W.F., et al. Effects of repeated subcutaneous administration of rhIGF-I in adults with growth hormone deficiency. Eur J Endocrinol. 131:1994;33-40.
189. Thompson J.L., Butterfield G.E., Marcus R., et al. The effects of rhIGF-I and growth hormone on body composition in elderly women. J Clin Endocrinol Metab. 80:1995;1845-1852.
190. Cioffi W.G., Gore D.C., Rue L.W., et al. Insulin-like growth factor-I lowers protein oxidation in patients with thermal injury. Ann Surg. 220:1994;310-316.
191. Vlachopapadopoulou E., Zacwieja J.J., Gertner J.M., et al. Metabolic and clinical response to rhIGF-I in myotonic dystrophy a clinical research center study . J Clin Endocrinol Metab. 80:1995;3715-3723.
192. Ghiron L.J., Thompson J.L., Holloway L., et al. Effects of recombinant insulin-like growth factor-I and growth hormone on bone turnover in elderly women. J Bone Miner Res. 10:1995;1844-1852.
193. Lieberman S.A., Butterfield G.E., Harrison D., et al. Anabolic effects of rhIGF-I in cachectic patients with the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 78:1994;404-410.
194. Waters D., Danska J., Hardy K., et al. Recombinant human growth hormone, IGF-I and combination therapy in AIDS-associated wasting. Ann Intern Med. 125:1996;865-872.
195. Ellis K.J., Lee P.D.K., Pivarnik J.M., et al. Changes in body composition of HIV-infected males receiving IGF-I and growth hormone. J Clin Endocrinol Metab. 81:1996;3033-3038.
196. Lee P.D.K., Pivarnik J.M., Bukar J.G., et al. A randomized, placebo-controlled trial of combined IGF-I and low dose growth hormone therapy for wasting associated with HIV infection. J Clin Endocrinol Metab. 81:1996;2968-2975.
197. Zenobi P.D., Glatz Y., Keller A., et al. Beneficial metabolic effects of IGF-I in patients with severe insulin-resistant diabetes type A. Eur J Endocrinol. 131:1994;251-257.
198. Backeljauw P.F., Alves C., Eidson M., et al. Effect of intravenous IGF-I in two patients with leprechaunism. Pediatr Res. 36:1994;749-754.
199. Mantzoros C.S., Moses A.C. Treatment of severe insulin resistance. Azziz R., Nestler J.E., Dewailly D. Androgen Excess Disorders in Women. 1997;247-255 Lippincott-Raven, Philadelphia.
200. Moses A.C., Morrow L.A., O'Brien M., et al. Insulin-like growth factor I as a therapeutic agent for hyperinsulinemic insulin-resistant diabetes mellitus. Diabetes Res Clin Pract. 28:(suppl):1995;185-194.
201. Moses A.C., Young S.C.J., Morrow L.A., et al. Recombinant hIGF-I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes. 45:1996;91-100.
202. De Boer H., Blok G.J., Popp-Snijders C., et al. Monitoring of growth hormone replacement therapy in adults based on measurement of serum markers. J Clin Endocrinol Metab. 81:1996;1371-1377.
203. Thoren M., Hilding A., Baxter R.C., et al. Serum IGF-I, IGFBP-1 and -3 and the acid labile subunit as serum markers of body composition during growth hormone therapy in adults with growth hormone deficiency. J Clin Endocrinol Metab. 82:1997;223-228.